Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
| العنوان: | Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer |
|---|---|
| المؤلفون: | Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel |
| المساهمون: | Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CH Morlaix, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de référence maladies rares des maladies pulmonaires rares de l’adulte (CHU Dijon) (CRMR des maladies pulmonaires rares de l’adulte), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon) |
| المصدر: | Frontiers in Medicine Frontiers in Medicine, Frontiers media, 2021, 8, ⟨10.3389/fmed.2021.691253⟩ Frontiers in Medicine, Vol 8 (2021) Frontiers in Medicine, 2021, 8, ⟨10.3389/fmed.2021.691253⟩ |
| بيانات النشر: | HAL CCSD, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Medicine (General), medicine.drug_class, Case Report, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, NSCLC, therapeutic assessment, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, R5-920, ROS1, Anaplastic lymphoma kinase, Medicine, Positron emission, Lung cancer, 030304 developmental biology, 0303 health sciences, crizotinib, Oncogene, Crizotinib, business.industry, Complete Metabolic Response, General Medicine, medicine.disease, FDG-PET/CT, 3. Good health, respiratory tract diseases, ALK, 030220 oncology & carcinogenesis, Cancer research, business, medicine.drug |
| الوصف: | Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography-computed tomography (18F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the 18F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC. |
| اللغة: | English |
| تدمد: | 2296-858X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce440c2b236cee057c7b25948262d4fTest https://hal.sorbonne-universite.fr/hal-03391339Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2ce440c2b236cee057c7b25948262d4f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2296858X |
|---|